Adverum Biotechnologies Inc ADVM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADVM is a good fit for your portfolio.
News
-
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
-
Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
-
Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
-
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
-
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
-
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
Trading Information
- Previous Close Price
- $8.09
- Day Range
- $7.81–8.58
- 52-Week Range
- $6.38–29.70
- Bid/Ask
- $7.92 / $8.80
- Market Cap
- $169.58 Mil
- Volume/Avg
- 300,745 / 414,616
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 121
- Website
- https://www.adverum.com
Comparables
Valuation
|
Metric
|
ADVM
|
VRDN
|
KDNY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.93 | 2.78 | 7.59 |
Price/Sales | — | 2,861.56 | 482.40 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADVM
|
VRDN
|
KDNY
|
|---|---|---|---|
Quick Ratio | 8.97 | 23.47 | 5.72 |
Current Ratio | 9.24 | 23.99 | 5.82 |
Interest Coverage | — | −104.84 | — |
Quick Ratio
ADVM
VRDN
KDNY
Profitability
|
Metric
|
ADVM
|
VRDN
|
KDNY
|
|---|---|---|---|
Return on Assets (Normalized) | −41.52% | −35.08% | −37.41% |
Return on Equity (Normalized) | −72.93% | −65.95% | −47.73% |
Return on Invested Capital (Normalized) | −44.76% | −42.29% | −43.85% |
Return on Assets
ADVM
VRDN
KDNY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Zcjftsszb | Vfl | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jksvcxr | Thqjqsw | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bfbswfh | Fwmkxgc | $118.7 Bil | |||
| Moderna Inc
MRNA
| Gtgqmxq | Qjyk | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sgcxjnsgw | Kgwzw | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Yktwmgtvw | Vrb | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Tgrwwzwcm | Dwyf | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nwsqpsv | Jzhtz | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Qfdqpsf | Hbyh | $15.0 Bil | |||
| Incyte Corp
INCY
| Hvtszbqb | Hyzdsm | $13.5 Bil |